Metformin and Kidney Function

eGFR Cutoffs, Dose Reduction and When to Stop — 2026 Practical Guide

A clear bedside algorithm for type 2 diabetes, CKD, acute illness and contrast imaging

THE 20-SECOND ANSWER

Think in eGFR, not serum creatinine alone. In 2026 ADA guidance, metformin should not be started when eGFR is <45 mL/min/1.73 m². If a patient is already taking it, reduce the dose when eGFR falls below 45, and stop it when eGFR falls below 30. Temporarily hold metformin during acute illnesses that may cause AKI or hypoperfusion, and around iodinated contrast in selected patients.

Metformin remains one of the most useful glucose-lowering drugs in type 2 diabetes — inexpensive, familiar, effective and with little hypoglycemia when used alone. But kidney function determines when it can be started, how much can be used, and when it should be paused or stopped. The mistake is to treat metformin as either “completely safe in CKD” or “forbidden as soon as creatinine rises.” The correct approach is more precise: use eGFR, recognize acute-risk situations, and distinguish long-term CKD from temporary kidney stress.

1. Why kidney function matters with metformin

Metformin is eliminated largely unchanged by the kidneys. As kidney function falls, drug clearance decreases and circulating metformin can accumulate.

The feared complication is metformin-associated lactic acidosis. It is rare, but risk rises when severe kidney dysfunction is combined with acute illness, hypoxia, sepsis, shock, dehydration, liver failure or another cause of impaired lactate clearance.

This is why the practical question is not simply “Does the patient have CKD?” It is “What is the current eGFR, is it stable, and is there any acute condition that could suddenly reduce renal perfusion or oxygen delivery?”

2. The eGFR traffic-light algorithm

eGFR	Start metformin?	If already taking it	Practical action
≥60	Yes	Continue usual tolerated dose	Routine renal monitoring; reassess if acute illness develops.
45–59	Yes	Continue	Monitor more closely if kidney function is declining or hypoperfusion/hypoxemia risk is present.
30–44	No new start	May continue at reduced dose	Reassess benefit-risk. A common evidence-based ceiling is about 1,000 mg/day; monitor eGFR every 3–6 months or more often if unstable.
<30	No	Stop	Metformin is contraindicated. Use another glucose-lowering strategy.

Important nuance: ADA 2026 says not to initiate metformin below eGFR 45, even though patients already receiving it may continue cautiously down to eGFR 30 with dose reduction and close monitoring. Local product labeling should always be checked.

3. Starting metformin versus continuing metformin: do not confuse the two

A patient with eGFR 38 who has never taken metformin is different from a stable patient whose eGFR has gradually fallen from 55 to 38 while taking metformin for years. In the first situation, current ADA guidance advises against starting metformin. In the second, metformin may often be continued at a lower dose with careful monitoring if the patient is otherwise stable.

Starting therapy: Avoid initiation if eGFR is <45 mL/min/1.73 m².
Already on therapy: Reduce the dose once eGFR is <45; reassess frequently.
Crossing below 30: Stop metformin.
Rapid fall in eGFR: Treat this as a warning sign. Look for AKI, dehydration, sepsis, nephrotoxins or hemodynamic compromise rather than simply changing the chronic dose.

4. Dose reduction and kidney monitoring

For eGFR 30–44 mL/min/1.73 m², the ADA/KDIGO consensus recommends reducing metformin to 1,000 mg daily. Dose reduction can also be considered at eGFR 45–59 in patients at increased risk of lactic acidosis because of hypoperfusion or hypoxemia.

Check eGFR at least annually in stable patients with preserved kidney function.
Once eGFR is <60 mL/min/1.73 m², monitoring every 3–6 months is reasonable; monitor more frequently if kidney function is changing rapidly.
Do not rely on a single creatinine value without context. Age, muscle mass and acute volume status can materially change interpretation.
A falling eGFR should also trigger a review of NSAIDs, diuretics, renin–angiotensin system blockers, volume status and intercurrent illness.

5. The sick-day rule: when metformin should be temporarily held

Most clinically important metformin accumulation occurs during an acute event, not because a stable CKD patient suddenly “cannot tolerate” the drug. Temporary interruption is therefore a major safety tool.

Vomiting, diarrhea or poor oral intake causing dehydration
Sepsis or serious systemic infection
Acute kidney injury or rapidly rising creatinine
Shock, severe hypotension or major hypoperfusion
Significant hypoxemia or respiratory failure
Acute decompensated heart failure with poor perfusion
Major surgery or hospitalization when renal/hepatic function may be unstable

Clinical pearl:
“Hold during dehydration/AKI; restart when eating, drinking and renal function are stable” is safer than memorizing metformin as permanently contraindicated in every patient with CKD.

6. Iodinated contrast: who needs metformin held?

Current ADA/FDA-based guidance supports temporary discontinuation at the time of or before iodinated contrast in patients with eGFR 30–60 mL/min/1.73 m². The FDA labeling also recommends holding it in patients with hepatic impairment, alcoholism or heart failure, and for intra-arterial iodinated contrast.

Before / at contrast: Hold metformin when the patient meets a risk criterion.
After contrast: Reassess kidney function about 48 hours later.
Restart: Restart only when renal function is stable and the patient is clinically well.

7. Metformin-associated lactic acidosis: rare, but know the setup

Metformin-associated lactic acidosis is uncommon. The risk is concentrated in patients with severe renal impairment or an acute event that simultaneously causes metformin accumulation and increased lactate production or impaired lactate clearance.

Higher-risk setting	Why it matters
eGFR <30	Metformin clearance is markedly reduced.
AKI / dehydration	Kidney function can deteriorate quickly.
Sepsis / shock	Lactate production and tissue hypoperfusion increase.
Severe hypoxemia	Anaerobic metabolism increases lactate.
Severe liver dysfunction	Lactate clearance may be impaired.

8. Metformin lowers glucose — it is not the kidney-protective drug

This distinction matters in modern diabetes care. Metformin remains a strong glucose-lowering foundation, but it has no proven direct kidney-protection outcome benefit. In type 2 diabetes with CKD, the organ-protective strategy is now layered:

Use an SGLT2 inhibitor with proven kidney benefit when eGFR is ≥20 mL/min/1.73 m² and clinically appropriate.
Use a GLP-1 receptor agonist with demonstrated cardiovascular/kidney benefit when indicated, particularly when additional glycemic or weight control is needed.
Treat albuminuric CKD comprehensively with blood-pressure control, RAS blockade when indicated, and finerenone in eligible patients with persistent albuminuria and normal potassium.

9. Do not forget vitamin B12

Long-term metformin can reduce vitamin B12 levels. ADA 2026 recommends periodic B12 assessment, particularly when anemia or peripheral neuropathy is present. This is clinically important because B12 deficiency can mimic or worsen diabetic neuropathy.

10. Five quick clinical scenarios

eGFR 72, newly diagnosed T2D → Metformin can be started if otherwise appropriate.

eGFR 52, stable CKD → Metformin can be started; monitor renal function more closely.

eGFR 38, never used metformin → Do not initiate under ADA 2026 guidance. Choose another agent based on phenotype and goals.

eGFR 38, taking metformin 2,000 mg/day → Do not automatically stop, but reduce the dose; 1,000 mg/day is a common consensus target, with close monitoring.

eGFR 26 → Stop metformin. For glycemic therapy in advanced CKD, GLP-1–based therapy not dependent on kidney clearance is often favored, individualized to the patient.

11. Common mistakes to avoid

Using serum creatinine alone instead of eGFR.
Starting metformin at eGFR 30–44 simply because “it is allowed down to 30.” Starting and continuing are not the same decision.
Continuing full-dose metformin after eGFR has fallen below 45.
Failing to pause metformin during dehydration, sepsis or AKI.
Forgetting to reassess renal function after iodinated contrast in a patient in whom metformin was held.
Assuming metformin itself provides the kidney-outcome benefit that belongs to SGLT2 inhibitors and selected GLP-1 therapies.
Missing B12 deficiency in a patient labeled as having “worsening diabetic neuropathy.”

12. Frequently asked questions

Can metformin be used in CKD?

Yes, in selected patients. The key threshold is eGFR. It may be used down to eGFR 30 in patients already receiving it, with dose reduction and monitoring; it should be stopped below 30.

Can I start metformin at eGFR 40?

Not according to ADA 2026 guidance. Do not initiate below eGFR 45.

Should metformin be stopped at eGFR 44?

Not automatically if the patient is already taking it and is stable. Reduce the dose, reassess benefit-risk and monitor kidney function.

Is metformin nephrotoxic?

No. Metformin does not directly injure the kidney. The concern is accumulation when kidney clearance becomes inadequate.

Does metformin protect the kidney?

It is useful for glycemic control but has no documented direct kidney-outcome benefit. SGLT2 inhibitors and selected GLP-1 therapies are the major organ-protective glucose-lowering classes in CKD.

When can metformin be restarted after an acute illness?

When the patient is clinically recovered, eating and drinking normally, and kidney function is stable.

Should B12 be checked in everyone taking metformin?

Periodic assessment is reasonable during long-term therapy, especially when anemia or peripheral neuropathy is present.

13. Exam-ready pearls

eGFR <45: do not START metformin.
eGFR 30–44: if already on metformin, REDUCE dose and monitor closely.
eGFR <30: STOP metformin.
Acute dehydration / sepsis / AKI / hypoxia: temporarily HOLD metformin.
Iodinated contrast + eGFR 30–60: temporarily HOLD; reassess renal function after ~48 hours before restarting.
Metformin does not directly damage kidneys — the concern is accumulation in renal failure.
Long-term metformin: remember vitamin B12 deficiency.

BOTTOM LINE

Metformin safety is about renal reserve + clinical stability. Do not start below 45. Reduce below 45 if already taking it. Stop below 30. Hold during acute kidney stress.

14. References

American Diabetes Association Professional Practice Committee. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S183–S215. Source
American Diabetes Association Professional Practice Committee. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S246–S260. Source
de Boer IH, et al. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the ADA and KDIGO. Diabetes Care. 2022;45:3075–3090. Source
S. prescribing information / FDA guidance for iodinated contrast and metformin precautions. Source

Clinical scope note: This article addresses nonpregnant adults with type 2 diabetes. Drug labels and contrast protocols can vary by country and institution. Individualize therapy to the patient, current renal function and acute clinical context.